# Esomeprazole for Treatment of GERD in Pediatric Patients

> **NCT00228527** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 100 (—)

## Conditions studied

- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Non-erosive Esophagitis

## Interventions

- **DRUG:** Esomeprazole (Nexium)

## Key facts

- **NCT ID:** NCT00228527
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 100 (—)
- **Last updated:** 2010-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228527, "Esomeprazole for Treatment of GERD in Pediatric Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00228527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*